Search

Your search keyword '"Venditti, Adriano"' showing total 1,167 results
Start Over Author "Venditti, Adriano"
1,167 results on '"Venditti, Adriano"'

1. Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group

Author

Forghieri, Fabio, Bettelli, Francesca, Sgromo, Simona, Nadali, Gianpaolo, Del Principe, Maria Ilaria, Buzzatti, Elisa, Farina, Francesca, Cesini, Laura, Giordano, Antonio, Criscuolo, Marianna, Facchinelli, Davide, Piedimonte, Monica, Sartor, Chiara, De Marchi, Roberta, Delia, Mario, Mosna, Federico, Cudillo, Laura, Tolomelli, Giulia, Basilico, Claudia Maria, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Lessi, Federica, Finizio, Olimpia, Zannetti, Beatrice Anna, Santoni, Adele, Fazi, Paola, Marchesi, Francesco, Venditti, Adriano, Candoni, Anna, Luppi, Mario, Busca, Alessandro, and Pagano, Livio

Published
2024
Full Text
View/download PDF

4. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Author

Efficace, Fabio, Kicinski, Michal, Coens, Corneel, Suciu, Stefan, van der Velden, Walter J. F. M., Noppeney, Richard, Chantepie, Sylvain, Griskevicius, Laimonas, Neubauer, Andreas, Audisio, Ernesta, Luppi, Mario, Fuhrmann, Stephan, Foà, Robin, Crysandt, Martina, Gaidano, Gianluca, Vrhovac, Radovan, Venditti, Adriano, Posthuma, Eduardus F. M., Candoni, Anna, Baron, Frédéric, Legrand, Olivier, Mengarelli, Andrea, Fazi, Paola, Vignetti, Marco, Giraut, Anne, Wijermans, Pierre W., Huls, Gerwin, and Lübbert, Michael

Published
2024
Full Text
View/download PDF

5. MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients

Author

Catalano, Gianfranco, Zaza, Alessandra, Banella, Cristina, Pelosi, Elvira, Castelli, Germana, de Marinis, Elisabetta, Smigliani, Ariela, Travaglini, Serena, Ottone, Tiziana, Divona, Mariadomenica, Del Principe, Maria Ilaria, Buccisano, Francesco, Maurillo, Luca, Ammatuna, Emanuele, Testa, Ugo, Nervi, Clara, Venditti, Adriano, Voso, Maria Teresa, and Noguera, Nelida Ines

Published
2023
Full Text
View/download PDF

6. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

Author

Paterno, Giovangiacinto, Palmieri, Raffaele, Tesei, Cristiano, Nunzi, Andrea, Ranucci, Giorgia, Mallegni, Flavia, Moretti, Federico, Meddi, Elisa, Tiravanti, Ilaria, Marinoni, Massimiliano, Page, Camilla, Fagiolo, Solaria, Buzzatti, Elisa, Secchi, Roberto, Gurnari, Carmelo, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria

Published
2024
Full Text
View/download PDF

9. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé, Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, and Huls, Gerwin

Published
2023
Full Text
View/download PDF

10. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting

Author

Attardi, Enrico, Savi, Arianna, Borsellino, Beatrice, Piciocchi, Alfonso, Cipriani, Marta, Ottone, Tiziana, Fabiani, Emiliano, Divona, Mariadomenica, Travaglini, Serena, Pascale, Maria Rosaria, Awada, Hussein, Durmaz, Arda, Visconte, Valeria, Della Porta, Matteo Giovanni, Venditti, Adriano, Maciejewski, Jaroslaw P., Gurnari, Carmelo, and Voso, Maria Teresa

Published
2023
Full Text
View/download PDF

11. CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML

Author

Travaglini, Serena, Ottone, Tiziana, Angelini, Daniela Francesca, Fiori, Valentina, Dominici, Sabrina, Noguera, Nelida Ines, Śniegocka, Martyna, Antonelli, Silvia, Irno Consalvo, Maria Antonietta, De Bardi, Marco, Banella, Cristina, Divona, Mariadomenica, Marchesi, Francesco, Masciarelli, Silvia, Fazi, Francesco, Pieraccioli, Marco, Palmieri, Raffaele, De Angelis, Gottardo, Buccisano, Francesco, Venditti, Adriano, Battistini, Luca, Magnani, Mauro, and Voso, Maria Teresa

Published
2022
Full Text
View/download PDF

13. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Author

Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano

Published
2022
Full Text
View/download PDF

14. Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications.

Author

Cicconi, Laura, Bisegna, Marialaura, Gurnari, Carmelo, Fanciullo, David, Piciocchi, Alfonso, Marsili, Giovanni, Minotti, Clara, Scalzulli, Emilia, Mandelli, Bianca, Guarnera, Luca, Perrone, Salvatore, Ortu La Barbera, Elettra, Mecarocci, Sergio, Biagi, Annalisa, Cenfra, Natalia, Corbingi, Andrea, Scerpa, Maria Cristina, Venditti, Adriano, Martelli, Maurizio, and Voso, Maria Teresa

Abstract

Summary: All‐trans‐retinoic acid (ATRA) and arsenic trioxide (ATO) represent the standard of care for low‐intermediate risk acute promyelocytic leukaemia (APL). Leucocytosis during induction with ATRA‐ATO represents a common complication with an incidence of up to 60%. To identify predictive factors for this complication, we studied a cohort of 65 low‐intermediate risk APL patients treated with ATRA‐ATO in three highly specialized Italian centres. Overall, 39/65 (60%) patients developed leucocytosis, with a peak in leucocyte count being most frequent in the second week from diagnosis. All cases were successfully managed with hydroxyurea. Predictive factors for leucocytosis in univariate analysis were lower platelet counts (odds ratio [OR] 0.98, 0.97–1.00, p = 0.018), lower fibrinogen levels (OR 0.36, 0.17–0.66, p = 0.003), higher bone marrow blast infiltration (OR 1.03, 1.01–1.07, p = 0.021) and CD117 expression by flow (OR 1.04, 1.01–1.08, p = 0.012). Multivariate analysis confirmed lower levels of fibrinogen at diagnosis as the strongest predictive factor for the development of leucocytosis (OR 0.36, 0.15–0.72, p = 0.009). Differentiation syndrome (DS) occurred only in patients developing leucocytosis showing a strict correlation with rising leucocytes counts (16/39 vs. 0/26, p < 0.001). In addition, other treatment‐related complications including QTc prolongation, cardiac events, liver, and haematological toxicities were significantly more frequent in patients experiencing leucocytosis (22/39 vs. 3/26, p < 0.001). In conclusion, APL patients undergoing ATRA‐ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment‐related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.

Author

Costa, Alessandro, Gurnari, Carmelo, Scalzulli, Emilia, Cicconi, Laura, Guarnera, Luca, Carmosino, Ida, Cerretti, Raffaella, Bisegna, Maria Laura, Capria, Saveria, Minotti, Clara, Iori, Anna Paola, Torrieri, Lorenzo, Venditti, Adriano, Pulsoni, Alessandro, Martelli, Maurizio, Voso, Maria Teresa, and Breccia, Massimo

Subjects
TREATMENT of acute promyelocytic leukemia, THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, HEMATOPOIETIC stem cell transplantation, CANCER relapse, PATIENTS, TRANSPLANTATION of organs, tissues, etc., ACUTE promyelocytic leukemia, SALVAGE therapy, PATHOLOGIC complete response, TREATMENT effectiveness, RETROSPECTIVE studies, CANCER patients, MULTIVARIATE analysis, ARSENIC compounds, CANCER chemotherapy, MEDICAL records, ACQUISITION of data, TRETINOIN, STATISTICS, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Relapses of acute promyelocytic leukemia (APL) remain a challenge despite the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Given the variability in salvage therapies and emerging evidence supporting the deferral of hematopoietic cell transplantation (HCT) in patients receiving ATO, we analyzed the outcomes of a multicentric cohort of 67 relapsed APL patients. Better outcomes were reported with ATO ± ATRA compared to chemo-based regimens and ATRA ± Gemtuzumab ozogamicin (GO). A significant survival advantage was observed for patients undergoing HCT in the chemo-based cohort (p = 0.017), but not in the ATO-based group (p = 0.12). Achieving molecular complete remission (CR) post salvage therapy emerged as the main prognostic factor for second relapses in both univariate and multivariate analyses. Our findings support the efficacy of ATO-based therapies in first relapse and enhance the role of molecular remission as an independent outcome predictor in both first and second APL relapses. Background: The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has radically improved the prognosis of acute promyelocytic leukemia (APL), with cure rates above 80%. While relapse occurs in less than 20% of cases, addressing this issue remains challenging. Identifying effective salvage therapies for relapsed APL is crucial to improve patient outcomes. Methods: A retrospective analysis was performed on a multicentric cohort of 67 APL patients in first relapse, treated in three Italian hematology centers from June 1981 to November 2021. The overall survival (OS) and cumulative incidence of relapse (CIR) were calculated, and predictive factors were assessed using Cox regression models. Results: Overall, 61 patients (91%) received ATO ± ATRA (40.3%), chemo-based regimens (40.3%), or ATRA ± Gemtuzumab ozogamicin (GO) (10.4%). Complete remission (CR) was achieved in 98.2% of patients (molecular CR, n = 71.4%). With a median follow-up time of 54.5 months, the 5-year OS was 73% in the ATO ± ATRA group, 44% in the chemo-based group, and 29% in the ATRA ± GO group (p = 0.035). The 5-year OS rate was also higher for transplant recipients vs. non-recipients within the chemo-based cohort (50% vs. 33%, p = 0.017), but not in the ATO-based cohort (p = 0.12). ATO-based salvage therapy resulted in better OS in both univariate (p = 0.025) and multivariate analyses (p = 0.026). The 2-year CIR was higher in patients without molecular CR vs. patients in molecular CR (66% vs. 24%, p = 0.034). Molecular CR was a significant predictor of second relapse in both univariate (p = 0.035) and multivariate analyses (p = 0.036). Conclusions: Our findings support the efficacy of ATO-based therapies in first relapse of APL and confirm the achievement of molecular remission as an independent outcome predictor in both first and second APL relapse. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, Carlo, Marcheselli, Luigi, Mina, Roberto, Sassone, Marianna, Guidetti, Anna, Penna, Domenico, Cattaneo, Chiara, Bonuomo, Valentina, Busca, Alessandro, Ferreri, Andrés José María, Bruna, Riccardo, Petrucci, Luigi, Cairoli, Roberto, Salvini, Marco, Bertù, Lorenza, Ladetto, Marco, Pilerci, Sofia, Pinto, Antonello, Ramadan, Safaa, Marchesi, Francesco, Cavo, Michele, Arcaini, Luca, Coviello, Elisa, Romano, Alessandra, Musto, Pellegrino, Massaia, Massimo, Fracchiolla, Nicola, Marchetti, Monia, Scattolin, Annamaria, Tisi, Maria Chiara, Cuneo, Antonio, Della Porta, Matteo, Trentin, Livio, Turrini, Marco, Gherlinzoni, Filippo, Tafuri, Agostino, Galimberti, Sara, Bocchia, Monica, Cardinali, Valeria, Cilloni, Daniela, Corso, Alessandro, Armiento, Daniele, Rigacci, Luigi, La Barbera, Elettra Ortu, Gambacorti-Passerini, Carlo, Visani, Giuseppe, Vallisa, Daniele, Venditti, Adriano, Selleri, Carmine, Conconi, Annarita, Tosi, Patrizia, Lanza, Francesco, Candoni, Anna, Krampera, Mauro, Corradini, Paolo, Passamonti, Francesco, and Merli, Francesco

Published
2022
Full Text
View/download PDF

19. Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial

Author

Efficace, Fabio, primary, Kicinski, Michal, additional, Coens, Corneel, additional, Suciu, Stefan, additional, van der Velden, Walter J.F.M, additional, Noppeney, Richard, additional, Chantepie, Sylvain P, additional, Griskevicius, Laimonas, additional, Neubauer, Andreas, additional, Audisio, Ernesta, additional, Luppi, Mario, additional, Fuhrmann, Stephan, additional, Foà, Robin, additional, Crysandt, Martina, additional, Gaidano, Gianluca, additional, Vrhovac, Radovan, additional, Venditti, Adriano, additional, Posthuma, Eduardus F.M., additional, Candoni, Anna, additional, Baron, Frédéric, additional, Legrand, Olivier, additional, Mengarelli, Andrea, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Giraut, Anne, additional, Wijermans, Pierre W., additional, Huls, Gerwin A, additional, and Lübbert, Michael, additional

Published
2024
Full Text
View/download PDF

20. Fatal acute graft-versus-host disease in Sezary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation

Author

Trotta, Gentiana Elena, primary, Ciangola, Giulia, additional, Cerroni, Ilaria, additional, Mezzanotte, Valeria, additional, Nunzi, Andrea, additional, Anemona, Lucia, additional, Savino, Luca, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Bonanni, Fabrizio, additional, Meddi, Elisa, additional, Zizzari, Annagiulia, additional, Rapisarda, Vito Mario, additional, Mangione, Ilaria, additional, Bruno, Antonio, additional, Cantonetti, Maria, additional, Venditti, Adriano, additional, and Cerretti, Raffaella, additional

Published
2024
Full Text
View/download PDF

21. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

Author

Piciocchi, Alfonso, primary, Cipriani, Marta, additional, Messina, Monica, additional, Marconi, Giovanni, additional, Arena, Valentina, additional, Soddu, Stefano, additional, Crea, Enrico, additional, Feraco, Maria Valeria, additional, Ferrante, Marco, additional, La Sala, Edoardo, additional, Fazi, Paola, additional, Buccisano, Francesco, additional, Voso, Maria Teresa, additional, Martinelli, Giovanni, additional, Venditti, Adriano, additional, and Vignetti, Marco, additional

Published
2024
Full Text
View/download PDF

24. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, Francesco, Cattaneo, Chiara, Arcaini, Luca, Bruna, Riccardo, Cavo, Michele, Merli, Francesco, Angelucci, Emanuele, Krampera, Mauro, Cairoli, Roberto, Della Porta, Matteo Giovanni, Fracchiolla, Nicola, Ladetto, Marco, Gambacorti Passerini, Carlo, Salvini, Marco, Marchetti, Monia, Lemoli, Roberto, Molteni, Alfredo, Busca, Alessandro, Cuneo, Antonio, Romano, Alessandra, Giuliani, Nicola, Galimberti, Sara, Corso, Alessandro, Morotti, Alessandro, Falini, Brunangelo, Billio, Atto, Gherlinzoni, Filippo, Visani, Giuseppe, Tisi, Maria Chiara, Tafuri, Agostino, Tosi, Patrizia, Lanza, Francesco, Massaia, Massimo, Turrini, Mauro, Ferrara, Felicetto, Gurrieri, Carmela, Vallisa, Daniele, Martelli, Maurizio, Derenzini, Enrico, Guarini, Attilio, Conconi, Annarita, Cuccaro, Annarosa, Cudillo, Laura, Russo, Domenico, Ciambelli, Fabrizio, Scattolin, Anna Maria, Luppi, Mario, Selleri, Carmine, Ortu La Barbera, Elettra, Ferrandina, Celestino, Di Renzo, Nicola, Olivieri, Attilio, Bocchia, Monica, Gentile, Massimo, Marchesi, Francesco, Musto, Pellegrino, Federici, Augusto Bramante, Candoni, Anna, Venditti, Adriano, Fava, Carmen, Pinto, Antonio, Galieni, Piero, Rigacci, Luigi, Armiento, Daniele, Pane, Fabrizio, Oberti, Margherita, Zappasodi, Patrizia, Visco, Carlo, Franchi, Matteo, Grossi, Paolo Antonio, Bertù, Lorenza, Corrao, Giovanni, Pagano, Livio, and Corradini, Paolo

Published
2020
Full Text
View/download PDF

26. Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle

Author

Rodríguez-Arbolí, Eduardo, primary, Othus, Megan, additional, Freeman, Sylvie, additional, Buccisano, Francesco, additional, Ngai, Lok Lam, additional, Thomas, Ian, additional, Palmieri, Raffaele, additional, Cloos, Jacqueline, additional, Johnson, Sean, additional, Meddi, Elisa, additional, Russell, Nigel H., additional, Venditti, Adriano, additional, Gradowska, Patrycja, additional, Ossenkoppele, Gert J., additional, Lowenberg, Bob, additional, and Walter, Roland B., additional

Published
2024
Full Text
View/download PDF

27. CT Images in Follicular Lymphoma: Changes after Treatment Are Predictive of Cardiac Toxicity in Patients Treated with Anthracycline-Based or R-B Regimens

Author

Esposito, Fabiana, primary, Mezzanotte, Valeria, additional, Tesei, Cristiano, additional, Luciano, Alessandra, additional, Gigliotti, Paola Elda, additional, Nunzi, Andrea, additional, Secchi, Roberto, additional, Angeloni, Cecilia, additional, Pitaro, Maria, additional, Meconi, Federico, additional, Cerocchi, Martina, additional, Garaci, Francesco, additional, Venditti, Adriano, additional, Postorino, Massimiliano, additional, and Chiocchi, Marcello, additional

Published
2024
Full Text
View/download PDF

28. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long‐term follow‐up of the EORTC‐GIMEMA randomized AML‐10 trial

Author

Baron, Frédéric, primary, Efficace, Fabio, additional, Cannella, Laura, additional, Stevens‐Kroef, Marian, additional, Amadori, Sergio, additional, de Witte, Theo, additional, Lübbert, Michael, additional, Venditti, Adriano, additional, and Suciu, Stefan, additional

Published
2024
Full Text
View/download PDF

29. Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel

Author

Girmenia, Corrado, primary, Ciceri, Fabio, additional, Corradini, Paolo, additional, Cuneo, Antonio, additional, D’Ancona, Fortunato, additional, Musto, Pellegrino, additional, Risitano, Antonio Maria, additional, Voso, Maria Teresa, additional, Venditti, Adriano, additional, and Barosi, Giovanni, additional

Published
2023
Full Text
View/download PDF

30. OVERLAPPING FEATURES OF HEPATIC COMPLICATIONS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN A RARE T-CELL LYMPHOMA: A CLINICAL CHALLENGE

Author

Nunzi, Andrea, primary, Ciangola, Giulia, additional, Cerroni, Ilaria, additional, Mezzanotte, Valeria, additional, Trotta, Gentiana Elena, additional, Meconi, Federico, additional, Zizzari, Annagiulia, additional, Rapisarda, Vito Mario, additional, Savino, Luca, additional, Brega, Arianna, additional, Argirò, Renato, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Bonanni, Fabrizio, additional, Meddi, Elisa, additional, Gurnari, Carmelo, additional, Bruno, Antoine, additional, Mangione, Ilaria, additional, Venditti, Adriano, additional, and Cerretti, Raffaella, additional

Published
2023
Full Text
View/download PDF

31. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Author

Efficace, Fabio, Cottone, Francesco, Sommer, Kathrin, Kieffer, Jacobien, Aaronson, Neil, Fayers, Peter, Groenvold, Mogens, Caocci, Giovanni, Lo Coco, Francesco, Gaidano, Gianluca, Niscola, Pasquale, Baccarani, Michele, Rosti, Gianantonio, Venditti, Adriano, Angelucci, Emanuele, Fazi, Paola, Vignetti, Marco, and Giesinger, Johannes

Published
2019
Full Text
View/download PDF

32. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Mazza, Patrizio, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Fabbiano, Francesco, Tafuri, Agostino, Chierichini, Anna, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Foà, Robin, Alati, Caterina, La Sala, Edoardo, Fazi, Paola, Vignetti, Marco, Maurillo, Luca, Buccisano, Francesco, Del Principe, Maria Ilaria, Irno-Consalvo, Maria, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Lo-Coco, Francesco, Arcese, William, and Amadori, Sergio

Published
2019
Full Text
View/download PDF

34. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Arena, Valentina, Palmieri, Raffaele, Filì, Carla, Carella, Angelo Michele, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Curti, Antonio, Luppi, Mario, Ingrosso, Claudia, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Mulè, Antonino, Tafuri, Agostino, Cudillo, Laura, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Trisolini, Silvia Maria, Alati, Caterina, La Sala, Edoardo, Maurillo, Luca, Del Principe, Maria Ilaria, Irno Consalvo, Maria Antonietta, Divona, Maria Domenica, Ottone, Tiziana, Cerretti, Raffaella, Sconocchia, Giuseppe, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, and Buccisano, Francesco

Published
2024
Full Text
View/download PDF

35. Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System.

Author

Sparano, Francesco, Giesinger, Johannes M., Gaidano, Gianluca, Anota, Amelie, Cavo, Michele, Brini, Alberto, Voso, Maria Teresa, Venditti, Adriano, Perrone, Francesco, Di Maio, Massimo, Luppi, Mario, Baron, Frederic, Platzbecker, Uwe, Fazi, Paola, Vignetti, Marco, and Efficace, Fabio

Subjects
HEALTH services accessibility, HEMATOLOGIC malignancies, SECONDARY analysis, SOCIOECONOMIC factors, QUESTIONNAIRES, MULTIPLE regression analysis, DESCRIPTIVE statistics, MANN Whitney U Test, FUNCTIONAL status, SYMPTOM burden, FINANCIAL stress, ODDS ratio, UNIVERSAL healthcare, QUALITY of life, RESEARCH, CANCER patient psychology, CONFIDENCE intervals, DATA analysis software, PSYCHOSOCIAL functioning, ECONOMIC aspects of diseases, DISEASE complications, PSYCHOSOCIAL factors
Abstract

PURPOSE: We investigated the association of financial toxicity (FT) with the health-related quality of life (HRQoL) profile of patients with hematologic malignancies treated in a universal health care system. METHODS: We did a secondary analysis of six multicenter studies enrolling patients with hematologic malignancies. FT was evaluated using the financial difficulties item of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Multivariable linear regression models were used to assess the mean differences in HRQoL scores between patients with or without FT, while adjusting for key potential confounding factors. We also examined the prevalence of clinically important problems and symptoms by the experience of FT, using established thresholds for the EORTC QLQ-C30. Multivariable binary logistic regression analysis was performed to explore the risk factors associated with FT. RESULTS: Overall, 1,847 patients were analyzed, of whom 441 (23.9%) reported FT. We observed statistically and clinically relevant worse scores for patients with FT compared with those without FT for all the EORTC QLQ-C30 scales. The three largest clinically relevant mean differences between patients with and without FT were observed in pain (∆ = 19.6 [95% CI, 15.7 to 23.5]; P <.001), social functioning (∆ = –18.9 [95% CI, –22.5 to –15.2]; P <.001), and role functioning (Δ = –17.7 [95% CI, –22.1 to –13.3]; P <.001). Patients with FT tended to report a higher prevalence of clinically important problems and symptoms across all EORTC QLQ-C30 scales. In the univariable and multivariable analyses, the presence of FT was associated with the presence of comorbidities, an Eastern Cooperative Oncology Group performance status ≥1, and not receiving a salary. CONCLUSION: Patients with hematologic malignancies treated in the setting of a universal health care system who experience FT have a worse HRQoL profile compared with those without FT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1

Author

Pelagalli, Martina, primary, Tomassetti, Flaminia, additional, Nicolai, Eleonora, additional, Giovannelli, Alfredo, additional, Codella, Silvia, additional, Iozzo, Mariannina, additional, Massoud, Renato, additional, Secchi, Roberto, additional, Venditti, Adriano, additional, Pieri, Massimo, additional, and Bernardini, Sergio, additional

Published
2023
Full Text
View/download PDF

38. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel

Author

Ravandi, Farhad, primary, Cloos, Jacqueline, additional, Buccisano, Francesco, additional, Dillon, Richard, additional, Döhner, Konstanze, additional, Freeman, Sylvie D., additional, Hourigan, Christopher S., additional, Ossenkoppele, Gerrit J., additional, Roboz, Gail J., additional, Subklewe, Marion, additional, Thiede, Christian, additional, Arnhardt, Isabell, additional, Valk, Peter J. M., additional, Venditti, Adriano, additional, Wei, Andrew H., additional, Walter, Roland B., additional, and Heuser, Michael, additional

Published
2023
Full Text
View/download PDF

40. Overlapping features of hepatic complications after hematopoietic cell transplantation in a rare T-cell lymphoma: A clinical challenge

Author

Nunzi, Andrea, Ciangola, Giulia, Cerroni, Ilaria, Mezzanotte, Valeria, Trotta, Gentiana Elena, Meconi, Federico, Zizzari, Annagiulia, Rapisarda, Vito Mario, Savino, Luca, Brega, Arianna, Argirò, Renato, De Angelis, Gottardo, Mariotti, Benedetta, Bonanni, Fabrizio, Meddi, Elisa, Gurnari, Carmelo, Bruno, Antoine, Mangione, Ilaria, Venditti, Adriano, and Cerretti, Raffaella

Published
2024
Full Text
View/download PDF

42. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Author

Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., and Ossenkoppele, Gert J.

Published
2018
Full Text
View/download PDF

45. P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

Author

Piciocchi, Alfonso, primary, Cipriani, Marta, additional, Messina, Monica, additional, Marconi, Giovanni, additional, Arena, Valentina, additional, Soddu, Stefano, additional, Crea, Enrico, additional, Valeria Feraco, Maria, additional, Ferrante, Marco, additional, la Sala, Edoardo, additional, Fazi, Paola, additional, Buccisano, Francesco, additional, Martinelli, Giovanni, additional, Venditti, Adriano, additional, and Vignetti, Marco, additional

Published
2023
Full Text
View/download PDF

46. P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD

Author

Piciocchi, Alfonso, primary, Marconi, Giovanni, additional, Cipriani, Marta, additional, Messina, Monica, additional, Guolo, Fabio, additional, Minetto, Paola, additional, Paoloni, Francesca, additional, Cotugno, Francesca, additional, DI Donato, Laura, additional, Simonetti, Giorgia, additional, Palmieri, Raffaele, additional, Buccisano, Francesco, additional, Fazi, Paola, additional, Vignetti, Marco, additional, M. Lemoni, Roberto, additional, Venditti, Adriano, additional, and Martinelli, Giovanni, additional

Published
2023
Full Text
View/download PDF

47. P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Author

Silvestrini, Giorgia, primary, Ottone, Tiziana, additional, Giovanni Piazza, Rocco, additional, Travaglini, Serena, additional, Gurnari, Carmelo, additional, Marchesi, Francesco, additional, Maria Nardozza, Anna, additional, Fabiani, Emiliano, additional, Attardi, Enrico, additional, Divona, Mariadomenica, additional, Ricci, Paola, additional, Antonietta Irno Consalvo, Maria, additional, Ienzi, Sara, additional, Arcese, Roberto, additional, Biagi, Annalisa, additional, Fiori, Luciano, additional, Novello, Mariangela, additional, Mauriello, Alessandro, additional, Venditti, Adriano, additional, Anemona, Lucia, additional, and Teresa Voso, Maria, additional

Published
2023
Full Text
View/download PDF

48. P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

Author

Venditti, Adriano, primary, Piciocchi, Alfonso, additional, Maurillo, Luca, additional, Ilaria Del Principe, Maria, additional, Palmieri, Raffaele, additional, Soddu, Stefano, additional, Moretti, Federico, additional, Salutari, Prassede, additional, Martelli, Maurizio, additional, Paola Martelli, Maria, additional, Luppi, Mario, additional, Pulsoni, Alessandro, additional, Zaja, Francesco, additional, Cairoli, Roberto, additional, Pane, Fabrizio, additional, Siragusa, Sergio, additional, Bassan, Renato, additional, Rondoni, Michela, additional, Mirabile, Milena, additional, Mulè, Antonino, additional, Beltrami, Germana, additional, Zappasodi, Patrizia, additional, Cudillo, Laura, additional, Mengarelli, Andrea, additional, Curti, Antonio, additional, Ferrara, Felicetto, additional, Rossi, Giovanni, additional, Audisio, Ernesta, additional, Spinosa, Giuseppina, additional, Tieghi, Alessia, additional, Bocchia, Monica, additional, Martini, Vincenza, additional, Califano, Catello, additional, Rigacci, Luigi, additional, Tafuri, Agostino, additional, Gottardi, Michele, additional, Fazi, Paola, additional, Vignetti, Marco, additional, and Buccisano, Francesco, additional

Published
2023
Full Text
View/download PDF

49. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

Author

Tettero, Jesse, primary, Palmieri, Raffaele, additional, Lam Ngai, Lok, additional, Bachas, Costa, additional, Arena, Valentina, additional, Breems, Dimitri, additional, Fischer, Thomas, additional, Tore Gjertsen, Bjorn, additional, Griškevičius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus, additional, Maurillo, Luca, additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Piciocchi, Alfonso, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Venditti, Adriano, additional, Ossenkoppele, Gert, additional, Buccisano, Francesco, additional, and Cloos, Jacqueline, additional

Published
2023
Full Text
View/download PDF

50. P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING

Author

Attardi, Enrico, primary, Savi, Arianna, additional, Borsellino, Beatrice, additional, Piciocchi, Alfonso, additional, Cipriani, Marta, additional, Ottone, Tiziana, additional, Fabiani, Emiliano, additional, Divona, Mariadomenica, additional, Travaglini, Serena, additional, Rosaria Pascale, Maria, additional, Durmaz, Arda, additional, Visconte, Valeria, additional, Giovanni Della Porta, Matteo, additional, Venditti, Adriano, additional, P Maciejewski, Jaroslaw, additional, Gurnari, Carmelo, additional, and Teresa Voso, Maria, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results